Unlocking Multiple Mechanisms of Action Using a Unique AI/ML Platform with Novel Immunomodulators for ARDS Patients

Time: 8:50 am


  • Highlighting the lead compound is Phase 2 ready for ARDS patients (including COVID-ARDS) having completed Phase 1
  • Using the unique AI/ML platform to develop 21 next generation p38 alpha/MK2 novel immunomodulators